Overview

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder and age associated memory impairment.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Treatments:
Mandelic Acids
Oxybutynin
Trospium chloride
Criteria
Inclusion Criteria:

- Patient presents symptoms of overactive bladder

- Patient has age associated memory impairment

- No acute or unstable medical conditions

Exclusion Criteria:

- History of alcohol or substance abuse within 1 year prior to study

- Has donated in excess of 500mL of blood or plasma in the 30 days prior to study

- Has known bleeding disorder (hemophilia)

- Previous abdominal bypass surgery for obesity